Trials / Completed
CompletedNCT03430830
A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
A Randomized, Open, Three-dose (100 mg, 200 mg and 300 mg) Duplicate Bifunctional Crossover and Fixed 200mg Continuous Dose Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics and safety of ASC16 after 3-single dose(50mg、100mg、200mg) or fixed continuous dose(200mg) in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ravidasvir 50mg | 50mg, Tablet |
| DRUG | Ravidasvir 200mg | 200mg, Tablet |
Timeline
- Start date
- 2018-01-15
- Primary completion
- 2018-04-09
- Completion
- 2018-04-09
- First posted
- 2018-02-13
- Last updated
- 2018-06-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03430830. Inclusion in this directory is not an endorsement.